Form 4: United Therapeutics Executive Exercises Options and Sells Shares Under Pre-Arranged Plan

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp., executed a planned exercise of stock options and subsequent sale of common shares on July 10, 2025, as disclosed in a recent SEC Form 4 filing.

Summary

• Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp. (UTHR), exercised 11,000 stock options at an exercise price of $135.42 per share on July 10, 2025.
• Concurrently, Mahon sold all 11,000 common shares acquired from the option exercise in multiple transactions on July 10, 2025.
• The sales were executed at weighted average prices ranging from $297.8874 for 600 shares, $299.4862 for 1,304 shares, $300.4792 for 7,738 shares, and $301.1953 for 1,358 shares.
• These transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, which was established on December 24, 2024.
• Following these reported transactions, Paul A. Mahon directly holds 36,781 shares of Common Stock and 110,000 derivative stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive to neutral. While insider selling can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling based on new negative information. The transactions represent a planned liquidity event for the executive, and the significant profit realized from the option exercise and subsequent sale is a positive for the individual.

Positives

• The transactions were executed under a pre-arranged 10b5-1 plan, which indicates a planned liquidity event for the executive rather than a reaction to new, negative information about the company.
• The executive realized a significant profit by exercising options at $135.42 and selling the resulting shares at prices around $300, demonstrating the substantial appreciation in the company's stock value.

Negatives

• Insider selling, even when conducted under a 10b5-1 plan, can sometimes be perceived by the market as a lack of increased conviction in the company's future prospects, as the insider chose to monetize shares rather than increase their direct holdings.

Future Outlook

This document is a report of past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is an insider transaction report and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the pre-arranged 10b5-1 plan reduces the negative implications typically associated with insider selling. The profit realized by the executive could be seen as an indicator of the company's stock performance.
• Employees, Customers, Suppliers, Creditors: No direct or material impact is indicated by this insider transaction report.

Key Dates

Keywords

United Therapeutics, UTHR, Form 4, insider trading, stock options, share sale, 10b5-1 plan, Paul A. Mahon, beneficial ownership, executive compensation